Selank & Semax

Selank and Semax are approved pharmaceuticals in Russia with real, if largely non-Western, human clinical trial data — but neither is FDA-approved for any use in the United States. This page describes their mechanisms and research history — not dosing or usage guidance, and not a recommendation to use them. Talk to a doctor before considering either.

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), studied as a nootropic and neuroprotective agent — proposed mechanisms include boosting brain-derived neurotrophic factor (BDNF) and modulating neurotransmitter systems involved in attention and recovery after brain injury. Selank is a synthetic analog of tuftsin, an immune-signaling peptide, studied primarily as an anxiolytic (anti-anxiety) agent believed to affect GABA and serotonin systems without the sedation or dependence risk associated with benzodiazepines.

Both have a genuinely unusual evidence base for this tier: real human clinical trials, not just animal data — but conducted almost entirely in Russia, with study designs and reporting standards that vary in rigor and don't always meet the bar international regulators like the FDA or EMA apply. Semax's clinical evidence includes trials in ischemic stroke recovery and optic nerve disease. Selank's evidence is concentrated in anxiety-disorder trials, including some head-to-head comparisons against benzodiazepines. This is meaningfully more human data than most Tier 2 entries have, but it comes from a research and regulatory tradition that Western agencies haven't independently validated.

Semax has been formally listed on Russia's Vital and Essential Drugs list since 2011. Selank is approved in Russia for generalized anxiety disorder and neurasthenia. Neither is FDA-approved in the United States. Their US compounding-pharmacy status differs: Semax was one of the peptides the FDA removed from its Category 2 "significant safety risk" list effective April 22, 2026, and in July 2026 an FDA advisory committee voted to recommend it for the compounding-permitted list — a recommendation, not a final rule, with formal rulemaking still pending. Selank's US bulk-substance nomination was separately withdrawn in 2024 and referred for advisory review; its outcome from that process is less clearly resolved in public reporting than Semax's, so treat its US compounding status as unsettled rather than assume it follows Semax.

FDA — Bulk Drug Substances Used in Compounding →

FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting